The JAK2 V617F mutation is not a cause of central retinal vein occlusion

• References

• 1 Prisco D, Marcucci R. Retinal vein thrombosis: risk factors, pathogenesis and therapeutic approach. Pathophysiol Haemost Thromb 2002; 32: 308-311.
• 2 Hayreh SS, Zimmerman MB, Beri M. et al. Intraocular pressure abnormalities associated with central and hemicentral retinal vein occlusion. Ophthalmology 2004; 111: 133-141.
• 3 Avashia JH, Fath DF. Bilateral central retinal vein occlusion in Waldenstrom's macroglobulinemia. J Am Optom Assoc 1989; 60: 657-658.
• 4 Hayreh SS, Zimmerman MB, Podhajsky P. Hematologic abnormalities associated with various types of retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 2002; 240: 180-196.
• 5 Fegan CD. Central retinal vein occlusion and thrombophilia. Eye 2002; 16: 98-106.
• 6 Michiels JJ, Berneman ZN, Schroyens W. et al. Pathophysiology and treatment of platelet-mediated microvascular disturbances, major thrombosis and bleeding complications in essential thrombocythaemia and polycythaemia vera. Platelets 2004; 15: 67-84.
• 7 Elliott MA, Tefferi A. Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. Br J Haematol 2005; 128: 275-290.
• 8 Michiels JJ, Koudstaal PJ, Mulder AH. et al. Transient neurologic and ocular manifestations in primary thrombocythemia. Neurology 1993; 43: 1107-1110.
• 9 Landolfi R, Marchioli R, Kutti J. et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med 2004; 350: 114-124.
• 10 James C, Ugo V, Casadevall N. et al. A JAK2 mutation in myeloproliferative disorders: pathogenesis and therapeutic and scientific prospects. Trends Mol Med 2005; 11: 546-554.
• 11 James C, Ugo V, Le Couedic JP. et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005; 434: 1144-1148.
• 12 Primignani M, Barosi G, Bergamaschi G. et al. Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis. Hepatology 2006; 44: 1528-1534.
• 13 Michiels JJ, Commandeur S, Hoogenboom GJ. et al. JAK2(V617F) positive early stage myeloproliferative disease (essential thrombocythemia) as the cause of portal vein thrombosis in two middle-aged women: therapeutic implications in view of the literature. Ann Hematol 2007; 86: 793-800.
• 14 Remacha AF, Estivill C, Sarda MP. et al. The V617F mutation of JAK2 is very uncommon in patients with thrombosis. Haematologica 2007; 92: 285-286.
• 15 Janssen HL, Leebeek FW. JAK2 mutation:The best diagnostic tool for myeloproliferative disease in splanchnic vein thrombosis?. Hepatology 2006; 44: 1391-1393.
• 16 De Stefano V, Fiorini A, Rossi E. et al. Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders. J Thromb Haemost 2007; 05: 708-714.
• 17 Tefferi A, Elliott M. Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2V617F. Semin Thromb Hemost 2007; 33: 313-320.
• 18 Michiels JJ, De RH, Hebeda K, Lam KH. et al. WHO bone marrow features and European clinical, molecular, and pathological (ECMP) criteria for the diagnosis of myeloproliferative disorders. Leuk Res 2007; 31: 1031-1038.
• 19 Arend O, Remky A, Jung F. et al. Role of rheologic factors in patients with acute central retinal vein occlusion. Ophthalmology 1996; 103: 80-86.
• 20 Baxter EJ, Scott LM, Campbell PJ. et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054-1061.
• 21 Heron E, Marzac C, Feldman-Billard S. et al. Endogenous erythroid colony formation in patients with retinal vein occlusion. Ophthalmology 2007; 114: 2155-2161.